Who Owns Gene Editing? Patents in the Time of CRISPR

Biochemist, Vol. 38, p. 26 (2016)

NYLS Legal Studies Research Paper No. 2915853

4 Pages Posted: 16 Feb 2017

See all articles by Jacob S. Sherkow

Jacob S. Sherkow

New York Law School; Columbia University - Department of Health Policy and Management; Center for Advanced Studies in Biomedical Innovation Law

Date Written: April 5, 2016

Abstract

New gene-editing technologies, like CRISPR, promise revolutionary advances in biology and medicine. However, several patent disputes in the USA and UK may have complicated who can use CRISPR. What does this mean for the future of gene editing?

Keywords: intellectual property, patent, biotech, biotechnology, crispr, genetics

JEL Classification: K00, K23, K41, O3, O34, D23, K11

Suggested Citation

Sherkow, Jacob S., Who Owns Gene Editing? Patents in the Time of CRISPR (April 5, 2016). Biochemist, Vol. 38, p. 26 (2016); NYLS Legal Studies Research Paper No. 2915853. Available at SSRN: https://ssrn.com/abstract=2915853

Jacob S. Sherkow (Contact Author)

New York Law School ( email )

185 West Broadway
New York, NY 10013
United States
212.431.2355 (Phone)

HOME PAGE: http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/

Columbia University - Department of Health Policy and Management ( email )

600 West 168th Street, 6th Floor
New York, NY 10032
United States

Center for Advanced Studies in Biomedical Innovation Law ( email )

Studiestraede 6
Studiestrade 6
Copenhagen, DK-1455
Denmark

HOME PAGE: http://jura.ku.dk/cebil/staff/

Register to save articles to
your library

Register

Paper statistics

Downloads
254
Abstract Views
731
rank
118,672
PlumX Metrics